Furthermore, inhibiting TGFB1 release reduced tumor stromal fibrosis, opened blood vessels, and enhanced the efficacy of the standard chemotherapy regimen, thereby significantly improving the survival of the orthotopic tumor‐bearing mice. This evidence concerns the gene TGFB1 and neoplasm.